INNATE PHARMA SA (IPHA) Social Stream
INNATE PHARMA SA (IPHA) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering INNATE PHARMA SA.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-03-25 | 2 | $11.5 | $9 | $10.25 | $2.79 | 267.38% |
| 2022-05-12 | 2 | $11.5 | $11 | $11.25 | $2.79 | 303.23% |
| 2022-08-02 | 2 | $11.5 | $10 | $10.75 | $2.79 | 285.3% |
| 2023-03-24 | 3 | $12 | $9 | $10.833 | $2.79 | 288.28% |
| 2023-06-02 | 3 | $12 | $10 | $11.166 | $2.79 | 300.22% |
| 2023-09-18 | 3 | $11.5 | $10 | $10.75 | $2.79 | 285.3% |
| 2023-11-14 | 3 | $11.5 | $8 | $9.833 | $2.79 | 252.44% |
The Trend in the Analyst Price Target
Over the past 20 months, IPHA's average price target has gone down $0.42.
IPHA reports an average of 271.74% for its upside potential over the past 34 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-03-24 | 3 | 12.0 | 9 | 10.833 | 2.88 | 276.15% |
| 2023-04-10 | 3 | 12.0 | 10 | 11.166 | 3.19 | 250.03% |
| 2023-09-18 | 3 | 11.5 | 8 | 9.833 | 2.75 | 257.56% |
| 2023-09-28 | 3 | 11.5 | 8 | 9.833 | 2.64 | 272.46% |
| 2023-11-14 | 3 | 11.5 | 8 | 9.833 | 2.58 | 281.12% |
IPHA Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1 | 3 | 0 | 0 | 0 | 0 | 3 |
The Trend in the Broker Recommendations
IPHA's average broker recommendation rating improved by 0 over the prior 23 months.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- In terms of how INNATE PHARMA SA fares relative to all US stocks, note that its number of analysts covering the stock is higher than 37.86% of that group.
- To contextualize these metrics, consider that out of all US stocks, INNATE PHARMA SA's upside potential (average analyst target price relative to current price) is greater than 630.46% of them.
- In the context of Pharmaceutical Products stocks, INNATE PHARMA SA's variance in analysts' estimates is lower than 27.85% of them.
- In terms of how INNATE PHARMA SA fares relative to Healthcare stocks, note that its average analyst price target is greater than 130.98% of that group.
In the Pharmaceutical Products industry, DTIL, GNFT, and INMB are the three stocks most similar to INNATE PHARMA SA regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
Is IPHA a Buy, Hold or Sell? See the POWR Ratings now!